NovaBay Stock Analysis

NBY
 Stock
  

USD 2.12  0.01  0.47%   

The big decline in price over the last few months for NovaBay Pharmaceuticalsmay encourage investors to take a closer look at the firm as it is trading at a share price of 2.12 on 9,224 in trading volume. The company directors and management failed to add value to investors and position the firm supply of money to exploit market volatility in November. However, diversifying your holdings with NovaBay Pharmaceuticals or similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 6.07. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the NovaBay Pharmaceuticals partners.
Additionally, see Correlation Analysis.
  
The NovaBay Pharmaceuticals stock analysis report makes it easy to digest most publicly released information about NovaBay Pharmaceuticals and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. NovaBay Stock analysis module also helps to analyze the NovaBay Pharmaceuticals price relationship with some important fundamental indicators such as market cap and management efficiency.

NovaBay Stock Analysis Notes

About 16.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.32. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. NovaBay Pharmaceuticals recorded a loss per share of 5.76. The entity had not issued any dividends in recent years. The firm had 1:35 split on the 16th of November 2022. NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California. Novabay Pharmaceuticals operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 29 people. To find out more about NovaBay Pharmaceuticals contact Justin Hall at 510 899 8800 or learn more at https://novabay.com.

NovaBay Pharmaceuticals Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. NovaBay Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding NovaBay Pharmaceuticals or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
NovaBay Pharmaceuticals generated a negative expected return over the last 90 days
NovaBay Pharmaceuticals has high historical volatility and very poor performance
The company reported the last year's revenue of 8.42 M. Reported Net Loss for the year was (5.82 M) with profit before taxes, overhead, and interest of 5.64 M.
NovaBay Pharmaceuticals has about 7.5 M in cash with (9.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.07.
Roughly 16.0% of the company outstanding shares are owned by corporate insiders

NovaBay Pharmaceuticals Upcoming and Recent Events

Earnings reports are used by NovaBay Pharmaceuticals to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to NovaBay Pharmaceuticals previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report24th of March 2022
Next Financial Report5th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End24th of March 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

NovaBay Largest EPS Surprises

Earnings surprises can significantly impact NovaBay Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2020-05-07
2020-03-31-0.07-0.060.0114 
2019-03-28
2018-12-31-0.08-0.070.0112 
2018-11-14
2018-09-30-0.11-0.090.0218 
View All Earnings Estimates

NovaBay Pharmaceuticals SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. NovaBay Pharmaceuticals prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that NovaBay Pharmaceuticals investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial NovaBay Pharmaceuticals specific information freely available to individual and institutional investors to make a timely investment decision.
13th of May 2022
Submission of Matters to a Vote of Security Holders
View
4th of February 2022
Unclassified Corporate Event
View

NovaBay Market Capitalization

The company currently falls under 'Nano-Cap' category with total capitalization of 4.27 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate NovaBay Pharmaceuticals's market, we take the total number of its shares issued and multiply it by NovaBay Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

NovaBay Profitablity

NovaBay Pharmaceuticals' profitability indicators refer to fundamental financial ratios that showcase NovaBay Pharmaceuticals' ability to generate income relative to its revenue or operating costs. If, let's say, NovaBay Pharmaceuticals is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, NovaBay Pharmaceuticals' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of NovaBay Pharmaceuticals' profitability requires more research than a typical breakdown of NovaBay Pharmaceuticals' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Net Profit Margin of (0.21) %, which means that it does not effectively control expenditures or properly executes on its pricing strategies. This is way below average. In the same way, it shows Net Operating Margin of (0.67) %, which entails that for every $100 of revenue, it lost -0.01.

Management Efficiency

The entity has Return on Asset of (0.2956) % which means that on every $100 spent on asset, it lost $0.2956. This is way below average. In the same way, it shows return on shareholders equity (ROE) of (79.2984) %, meaning that it generated no profit with money invested by stockholders. NovaBay Pharmaceuticals management efficiency ratios could be used to measure how well novabay pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 1st of December, NovaBay Pharmaceuticals secures the risk adjusted performance of (0.45), and Mean Deviation of 4.25. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of NovaBay Pharmaceuticals, as well as the relationship between them. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of past prices, or the prices will eventually revert. We have analyzed nineteen technical drivers for NovaBay Pharmaceuticals, which can be compared to its peers in the industry. Please verify NovaBay Pharmaceuticals jensen alpha and semi variance to decide if NovaBay Pharmaceuticals is priced some-what accurately, providing market reflects its recent price of 2.12 per share. Please also check out NovaBay Pharmaceuticals total risk alpha, which is currently at (2.09) to check the company can sustain itself at a future point.

NovaBay Pharmaceuticals Price Movement Analysis

The output start index for this execution was three with a total number of output elements of fifty-eight. NovaBay Pharmaceuticals Triple Exponential Moving Average indicator shows smoothing effect of NovaBay Pharmaceuticals price series composite of a single exponential moving average, a double exponential moving average and a triple exponential moving average.
.

NovaBay Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific NovaBay Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on NovaBay Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases NovaBay Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

NovaBay Pharmaceuticals Predictive Daily Indicators

NovaBay Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of NovaBay Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

NovaBay Pharmaceuticals Forecast Models

NovaBay Pharmaceuticals time-series forecasting models is one of many NovaBay Pharmaceuticals' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary NovaBay Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About NovaBay Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how NovaBay Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling NovaBay shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as NovaBay Pharmaceuticals. By using and applying NovaBay Stock analysis, traders can create a robust methodology for identifying NovaBay entry and exit points for their positions.
NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California. Novabay Pharmaceuticals operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 29 people.

Current NovaBay Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. NovaBay analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. NovaBay analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
2.2Strong Buy1Odds
NovaBay Pharmaceuticals current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most NovaBay analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand NovaBay stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of NovaBay Pharmaceuticals, talking to its executives and customers, or listening to NovaBay conference calls.
NovaBay Analyst Advice Details

NovaBay Stock Analysis Indicators

NovaBay Pharmaceuticals stock analysis indicators help investors evaluate how NovaBay Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading NovaBay Pharmaceuticals shares will generate the highest return on investment. By understating and applying NovaBay Pharmaceuticals stock analysis, traders can identify NovaBay Pharmaceuticals position entry and exit signals to maximize returns.
Begin Period Cash Flow12427000.00
Common Stock Shares Outstanding618314.29
Total Stockholder Equity10171000.00
DescriptionNovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally. It offers Avenova, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid and wound care products under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to addr
Total Cashflows From Investing Activities-12045000.00
Property Plant And Equipment Net604000.00
Retained Earnings-141887000.00
Cash And Short Term Investments7504000.00
Cash7504000.00
CodeNBY
Accounts Payable1045000.00
Net Debt-6953000.00
50 Day M A3.437
Total Current Liabilities3442000.00
Currency CodeUSD
Other Operating Expenses17283000.00
Non Current Assets Total10808000.00
Non Currrent Assets Other476000.00
Additionally, see Correlation Analysis. Note that the NovaBay Pharmaceuticals information on this page should be used as a complementary analysis to other NovaBay Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try CEO Directory module to screen CEOs from public companies around the world.

Complementary Tools for NovaBay Stock analysis

When running NovaBay Pharmaceuticals price analysis, check to measure NovaBay Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NovaBay Pharmaceuticals is operating at the current time. Most of NovaBay Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NovaBay Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move NovaBay Pharmaceuticals' price. Additionally, you may evaluate how the addition of NovaBay Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Is NovaBay Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NovaBay Pharmaceuticals. If investors know NovaBay will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NovaBay Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
4.3 M
Quarterly Revenue Growth YOY
0.69
Return On Assets
(0.30) 
Return On Equity
(79.30) 
The market value of NovaBay Pharmaceuticals is measured differently than its book value, which is the value of NovaBay that is recorded on the company's balance sheet. Investors also form their own opinion of NovaBay Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is NovaBay Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NovaBay Pharmaceuticals' market value can be influenced by many factors that don't directly affect NovaBay Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NovaBay Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine NovaBay Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NovaBay Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.